Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Date:8/21/2008


Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI'

Implements immediate restructuring program, which extends cash runway

while focusing on clinical pipeline programs

BOTHELL, WA, Aug. 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company has completed its acquisition of OncoGenex Technologies and NASDAQ has approved the commencement of trading in Company's common stock on The NASDAQ Capital Market under the stock symbol 'OGXI' effective today, August 21, 2008, when the market opens. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split.

"Clearly the shareholders of both companies, Sonus Pharmaceuticals and OncoGenex Technologies, strongly favored this transaction and our efforts to maintain a NASDAQ listing," said Scott Cormack, President and Chief Executive Officer of OncoGenex Pharmaceuticals. "On August 19th, a very strong percentage of Sonus' shareholders voted in favor of the transaction and voted in favor of a reverse stock split. One hundred percent of OncoGenex Technologies' shareholders voted in favor of the transaction."

Additionally, as announced on August 20th, the Company has implemented cost-saving measures to preserve cash while focusing on its highest potential product development programs. The Company will reduce workforce by approximately 49%. As a result of these actions, the Company will incur approximately $1.2 million in charges in the third quarter of 2008, associated with employee severance costs. Management estimates that
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... a webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based ... energy. Touted as 'the wonder material of the 21st Century' by the ...
(Date:6/30/2015)... Americord Registry, one of the fastest growing cord blood banks ... at Kirkland & Ellis LLP, as the newest member of ...   "We are thrilled about Andrew Horne,s ... , CEO of Americord. "He brings a wealth of knowledge ... growth and vision." Andrew Horne is ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... - Ranked Number 7 out of top 20 Employers ... 9 EMD Serono, Inc., an affiliate,of Merck KGaA, ... Science magazine as a top employer in the biotechnology ... 20 employers,across the life sciences., "We are honored ...
... (Nasdaq: ERES ), a leading provider of ... to the pharmaceutical,biotechnology, medical device, and related industries, ... quarter results for the period ended,September 30, 2008 ... closes.,After the release, the Company will host a ...
... Million RMB Commercial Bank Loan With Interest Payment ... Biotech Ltd. (Amex:,SVA), a vaccine-focused biotech company in ... Promotion Association at the,Zhongguancun Science and Technology Park ... of that program, Sinovac Biotech Co. Ltd.,s,("the Company") ...
Cached Biology Technology:EMD Serono Named as a Top Employer by Science Magazine 2eResearchTechnology, Inc. to Announce 2008 Third Quarter Results on October 30, 2008 2Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 2Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 3
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... June 22, 2015 ... addition of the "Body-Worn Temperature Sensors Market ... and Forecast 2014 - 2020" report to ... analysis of the global body-worn temperature sensors market. ... segmented on the basis of types, care setting, ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... goats and other animals that have suffered from neglect, according ... In this first scientific study of rescued animals, the researchers ... poor welfare, such as inappropriate diet, and lack of space ... spatial awareness test, which involved giving the animals an opportunity ...
... special issue of Technology and Innovation ... ), devoted to studies on medical technology and health ... from new technologies to reduce the cost of health ... special issue of Technology and Innovation on ...
... gas development expands nationwide, policymakers, communities and public health ... as a means of predicting the effects of drilling ... the Colorado School of Public Health. The report, ... Public Health , highlights lessons learned when scientists from ...
Cached Biology News:Rescue me: New study finds animals do recover from neglect 2Technology transforms health care 2Technology transforms health care 3Health impact assessments prove critical public health tool 2
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: